Position paper - AmCham EU's response to the inception impact assessment on the revision of the EU legislation on medicines for children and rare diseases.

AmCham EU's response to the inception impact assessment on the revision of the EU legislation on medicines for children and rare diseases. We encourage the Commission to protect the frameworks that stimulate R&D, build on the EU’s strengths and incorporate learnings from other regions